Premium Nahrungsergänzungsmittel | artgerecht

PTLD: Causes, Symptoms & Treatment

PTLD (Post-Transplant Lymphoproliferative Disease) is a rare but serious complication after organ transplantation, characterized by uncontrolled growth of lymphoid cells.

Regular tips about health Regular tips about health

Things worth knowing about "PTLD"

PTLD (Post-Transplant Lymphoproliferative Disease) is a rare but serious complication after organ transplantation, characterized by uncontrolled growth of lymphoid cells.

What is PTLD?

PTLD stands for Post-Transplant Lymphoproliferative Disease (or Disorder). It is a rare but potentially life-threatening complication that can occur in patients who have received an organ or stem cell transplant. In PTLD, lymphocytes (white blood cells) multiply in an uncontrolled manner. The disease encompasses a wide spectrum of conditions, ranging from benign lymphoid proliferations to highly aggressive lymphomas.

Causes

The primary cause of PTLD is the immunosuppressive therapy used after transplantation to prevent organ rejection. By suppressing the immune system, the body loses its ability to control certain viral infections, most notably the Epstein-Barr virus.

Epstein-Barr Virus (EBV): EBV plays a central role in most PTLD cases. The virus can infect B-lymphocytes and drive their uncontrolled proliferation when the immune system is suppressed and cannot mount an adequate response.
Type of transplant: The risk is particularly high following stem cell transplants, as well as lung, small bowel, and heart transplants.
Degree of immunosuppression: The more intensive the immunosuppressive regimen, the higher the risk of developing PTLD.
EBV serostatus: EBV-negative recipients who receive an organ from an EBV-positive donor are at especially high risk, as they have no prior immunity to the virus.

Symptoms

PTLD symptoms are diverse and depend on the organs affected and the severity of the disease. Common symptoms include:

Swollen lymph nodes (lymphadenopathy)
Fever, night sweats, and unexplained weight loss (so-called B-symptoms)
Fatigue and general malaise
Enlargement of the spleen and liver (splenomegaly, hepatomegaly)
Organ-specific symptoms (e.g., abdominal pain if the gastrointestinal tract is involved, or neurological symptoms if the central nervous system is affected)
Increased susceptibility to infections

Diagnosis

Diagnosing PTLD requires a combination of clinical assessment and diagnostic tests:

Blood tests: EBV viral load (EBV DNA PCR), complete blood count, lactate dehydrogenase (LDH) levels
Imaging: CT scan or PET-CT to detect enlarged lymph nodes and affected organs
Biopsy: Tissue sampling from an affected lymph node or organ, followed by histological and immunohistochemical analysis, is essential for a definitive diagnosis.
Classification: PTLD is classified according to the WHO classification into subtypes such as early lesions, polymorphic PTLD, monomorphic PTLD, and classic Hodgkin lymphoma-type PTLD.

Treatment

Treatment of PTLD depends on the subtype, disease extent, and the overall condition of the patient. The main treatment strategies include:

Reduction of Immunosuppression

The first step in managing PTLD is often reducing the immunosuppressive medications. This allows the patient's immune system to recover and fight the abnormal lymphocytes. However, this approach carries the risk of organ rejection and must be carefully balanced.

Rituximab

Rituximab is a monoclonal antibody that specifically targets the CD20 protein on B-lymphocytes. It is used in EBV-associated, CD20-positive PTLD and has significantly improved treatment outcomes.

Chemotherapy

For aggressive or rituximab-refractory forms of PTLD, chemotherapy regimens such as R-CHOP are used.

Antiviral Therapy

Antiviral agents such as ganciclovir or valganciclovir may be used in selected cases, particularly for prophylaxis in patients with high EBV viral loads.

Additional Options

Specialized centers may also offer adoptive T-cell therapies using EBV-specific cytotoxic T-lymphocytes, as well as radiation therapy for localized disease.

Prognosis

The prognosis of PTLD varies considerably depending on the subtype and treatment response. Early and polymorphic forms often respond well to reduction of immunosuppression. Monomorphic forms, particularly diffuse large B-cell lymphoma, carry a poorer prognosis and require more intensive treatment. Early detection and prompt initiation of appropriate therapy are key to improving outcomes.

References

Swerdlow SH et al. - WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th Edition. IARC Press, Lyon, 2017.
Allen UD, Preiksaitis JK; AST Infectious Diseases Community of Practice - Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation, 2019. PubMed PMID: 31230381.
Dierickx D, Habermann TM - Post-Transplantation Lymphoproliferative Disorders in Adults. New England Journal of Medicine, 2018. PubMed PMID: 29365301.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category